Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer.
Shabason JE, Chen J, Apisarnthanarax S, Damjanov N, Giantonio B, Loaiza-Bonilla A, O'Dwyer PJ, O'Hara M, Reiss KA, Teitelbaum U, Wissel P, Drebin JA, Vollmer C, Kochman M, Mick R, Vergara N, Jhala N, Doucette A, Lukens JN, Plastaras JP, Metz JM, Ben-Josef E. Shabason JE, et al. Cancer Chemother Pharmacol. 2018 Mar;81(3):609-614. doi: 10.1007/s00280-018-3519-6. Epub 2018 Jan 23. Cancer Chemother Pharmacol. 2018. PMID: 29362902 Clinical Trial.
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.
Karasic TB, O'Hara MH, Loaiza-Bonilla A, Reiss KA, Teitelbaum UR, Borazanci E, De Jesus-Acosta A, Redlinger C, Burrell JA, Laheru DA, Von Hoff DD, Amaravadi RK, Drebin JA, O'Dwyer PJ. Karasic TB, et al. JAMA Oncol. 2019 Jul 1;5(7):993-998. doi: 10.1001/jamaoncol.2019.0684. JAMA Oncol. 2019. PMID: 31120501 Free PMC article. Clinical Trial.
Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer.
Arscott WT, Nead KT, Bear A, Venigalla S, Shabason J, Lukens JN, Plastaras JP, Wojcieszynski A, Metz J, O'Hara M, Reiss KA, Teitelbaum U, Loaiza-Bonilla A, Drebin J, Lee MK 4th, Shroff SG, Ben-Josef E. Arscott WT, et al. Among authors: loaiza bonilla a. Am J Clin Oncol. 2021 Sep 1;44(9):469-474. doi: 10.1097/COC.0000000000000854. Am J Clin Oncol. 2021. PMID: 34310350 Free PMC article. Clinical Trial.
Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX.
Peterson SL, Husnain M, Pollack T, Pimentel A, Loaiza-Bonilla A, Westendorf-Overley C, Ratermann K, Anthony L, Desimone P, Goel G, Kudrimoti M, Dineen S, Tzeng CD, Hosein PJ. Peterson SL, et al. Anticancer Res. 2018 Jul;38(7):4035-4039. doi: 10.21873/anticanres.12692. Anticancer Res. 2018. PMID: 29970528 Free PMC article.
Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma.
Khushman M, Dempsey N, Maldonado JC, Loaiza-Bonilla A, Velez M, Carcas L, Dammrich D, Hurtado-Cordovi J, Parajuli R, Pollack T, Harwood AP, Macintyre J, Tzeng CW, Merchan JR, Restrepo MH, Akunyili II, Ribeiro A, Narayanan G, Portelance L, Sleeman D, Levi JU, Lima CM, Hosein PJ. Khushman M, et al. Pancreatology. 2015 Nov-Dec;15(6):667-73. doi: 10.1016/j.pan.2015.08.010. Epub 2015 Sep 12. Pancreatology. 2015. PMID: 26412296
44 results